Healthcare / Medical DevicesTaipei Exchange
$11.40
+0.45 (+4.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $30.5M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$540M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-19.2%
↓Gross Margin
17.6%
↓Debt/Equity
0.61
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.7%
FCF CAGR
—
FCF margin
-1.3%
FCF / Net income
0.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $398.0M · net income $-61.7M · FCF $-5.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $398.0M | $398.0M | $706.4M | $601.2M | $797.5M |
| Net Income | $-61.7M | $-61.7M | $24.2M | $-33.2M | $-17.5M |
| EBITDA | $-46.7M | $-46.7M | $55.6M | $-7.8M | $11.8M |
| EPS | — | — | 0.48 | -0.70 | -0.37 |
| Gross Margin | 17.6% | 17.6% | 20.9% | 15.5% | 12.3% |
| Operating Margin | -15.9% | -15.9% | 0.4% | -6.7% | -5.7% |
| Net Margin | -15.5% | -15.5% | 3.4% | -5.5% | -2.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.61 | 0.61 | 0.54 | 0.34 | 0.51 |
| Current Ratio | 2.81 | 2.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.0M | $-5.0M | $30.5M | $76.8M | $-93.0M |
| Returns | |||||
| ROE | -19.2% | -19.2% | 6.2% | -9.9% | -4.7% |
| Valuation | |||||
| P/E | — | — | 37.60 | — | — |
| EV/EBITDA | — | — | 15.15 | — | 62.39 |
| P/B | 1.69 | 1.69 | 2.18 | 2.39 | 1.90 |
| Growth & Yield | |||||
| Revenue Growth | -43.7% | -43.7% | 17.5% | -24.6% | — |
| EPS Growth | — | — | 168.6% | -89.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.48 → n/d
Residual
-24.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.